46.0¢
An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 46.0¢ | Day High | 46.5¢ | Day Low | 46.0¢ | |||
| Daily Volume | 42565 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 3 | 46.0¢ | 41004 | 2 | 46.5¢ | 38272 | |
| Mr. James Hamilton Bray Graham | Chief Executive Officer, Managing Director, Executive Director |
| Mr. Justin Reynolds | Chief Financial Officer |
| Ms. Michele Keryn Dilizia | Chief Scientific Officer, Executive Director |
| Dr. Philip Sutton | Vice President of Translational Sciences |
| Dr. Justin Ward | Executive Director and Principal Quality Chemist |
| Mr. Daniel Astudillo | Head of Marketing |
| Mr. Thomas Jarrett | Operations Manager |
| Ms. Maggie Niewidok | Company Secretary |
| Dr. John Prendergast | Independent Non- Executive Chairman of the Board |
| Mr. Alistair McKeough | Non-Executive Director |
| Dr. Alan William Dunton | Non-Executive Independent Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $102.0M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 46.5¢ | 46.0¢ | $19.60K | 42.56K |
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 41004 | 46.0¢ |
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 38272 | 2 |
| Last trade - 15.56pm 26/07/2024 (20 minute delay) ? |
|
|||||
|
Last
46.0¢ |
Change
0.000 ( 1.08 %) |
||||
| Open | High | Low | Volume | ||
| 46.0¢ | 47.0¢ | 46.0¢ | 5566 | ||
| Last updated 12.56pm 26/07/2024 ? | |||||
| RCE (ASX) Chart |
